Form 4: Dermata Therapeutics Director Acquires Stock Options

Kathleen D. Scott, a director at Dermata Therapeutics, acquired 5,000 stock options on January 13, 2025.

Summary

• Kathleen D. Scott, a director of Dermata Therapeutics, acquired 5,000 stock options on January 13, 2025.
• The options have an exercise price of $1.38 per share.
• The options vest in twelve equal monthly installments, starting one month after the grant date, contingent on continuous service.
• The options expire on January 12, 2035.

Sentiment

Score: 6

Explanation: The document is a routine filing of a stock option grant to a director. It is neither particularly positive nor negative, but it does indicate that a director is incentivized to see the company succeed.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.

Risks

• The vesting of the options is contingent on the director's continued service, which could be a risk if the director leaves the company.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's securities. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies as part of their compensation packages.
• The vesting schedule of 12 months is also a typical arrangement to incentivize long-term commitment from directors.
• The exercise price of $1.38 is specific to Dermata Therapeutics and would need to be compared to other similar companies to assess its relative value.

Stakeholder Impact

• The stock option grant could be seen positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

stock options, director, Dermata Therapeutics, DRMA, insider trading, equity, vesting